These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 22155841)

  • 1. The scopolamine model of dementia: determination of central cholinomimetic effects of physostigmine on cognition and biochemical markers in man.
    Preston GC; Brazell C; Ward C; Broks P; Traub M; Stahl SM
    J Psychopharmacol; 1988 Jan; 2(2):67-79. PubMed ID: 22155841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FK960 [N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate], a novel potential antidementia drug, improves visual recognition memory in rhesus monkeys: comparison with physostigmine.
    Matsuoka N; Aigner TG
    J Pharmacol Exp Ther; 1997 Mar; 280(3):1201-9. PubMed ID: 9067304
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physostigmine challenge before and after chronic cholinergic blockade in elderly volunteers.
    Dukoff R; Wilkinson CW; Lasser R; Friz J; Conway A; Bahro M; Peskind ER; Sunderland T
    Biol Psychiatry; 1999 Jul; 46(2):189-95. PubMed ID: 10418693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interactions between scopolamine and muscarinic cholinergic agonists or cholinesterase inhibitors on spatial alternation performance in rats.
    Shannon HE; Bemis KG; Hendrix JC; Ward JS
    J Pharmacol Exp Ther; 1990 Dec; 255(3):1071-7. PubMed ID: 2262893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Further evidence for the cholinergic hypothesis of aging and dementia from the canine model of aging.
    Araujo JA; Studzinski CM; Milgram NW
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Mar; 29(3):411-22. PubMed ID: 15795050
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholinergic potentiation of the meal-related rise in ACTH and cortisol concentrations in men.
    Dodt C; Hansen K; Uthgenannt D; Born J; Fehm HL
    Exp Clin Endocrinol; 1994; 102(6):460-6. PubMed ID: 7890023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cortisol responses to cholinergic drugs in Alzheimer's disease.
    Kumar V; Smith RC; Sherman KA; Ashford W; Murphy J; Giacobini E; Colliver J
    Int J Clin Pharmacol Ther Toxicol; 1988 Oct; 26(10):471-6. PubMed ID: 3069749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Scopolamine-induced learning impairment reversed by physostigmine in zebrafish.
    Kim YH; Lee Y; Kim D; Jung MW; Lee CJ
    Neurosci Res; 2010 Jun; 67(2):156-61. PubMed ID: 20298728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scopolamine and benzodiazepine models of dementia: cross-reversals by Ro 15-1788 and physostigmine.
    Preston GC; Ward C; Lines CR; Poppleton P; Haigh JR; Traub M
    Psychopharmacology (Berl); 1989; 98(4):487-94. PubMed ID: 2570433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of the effects of cholinergic and dopaminergic agents on scopolamine-induced hyperactivity in mice.
    Shannon HE; Peters SC
    J Pharmacol Exp Ther; 1990 Nov; 255(2):549-53. PubMed ID: 2243341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of thyrotropin-releasing hormone and scopolamine in Alzheimer's disease and normal volunteers.
    Molchan SE; Mellow AM; Hill JL; Weingartner H; Martinez R; Vitiello B; Sunderland T
    J Psychopharmacol; 1992 Jan; 6(4):489-500. PubMed ID: 22291397
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The scopolamine model of dementia: chronic transdermal administration.
    Brazell C; Preston GC; Ward C; Lines CR; Traub M
    J Psychopharmacol; 1989 Jan; 3(2):76-82. PubMed ID: 22156502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of cognitive impairment by heptyl physostigmine, a long-lasting cholinesterase inhibitor, in primates.
    Rupniak NM; Tye SJ; Brazell C; Heald A; Iversen SD; Pagella PG
    J Neurol Sci; 1992 Feb; 107(2):246-9. PubMed ID: 1564524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aging and cholinergic modulation of the transient magnetic 40-Hz auditory response.
    Ahveninen J; Jääskeläinen IP; Kaakkola S; Tiitinen H; Pekkonen E
    Neuroimage; 2002 Jan; 15(1):153-8. PubMed ID: 11771983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cholinergic modulation of spatial learning in mice in a Morris-type water maze.
    Lamberty Y; Gower AJ
    Arch Int Pharmacodyn Ther; 1991; 309():5-19. PubMed ID: 1888229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Probing peripheral and central cholinergic system responses.
    Naranjo CA; Fourie J; Herrmann N; Lanctôt KL; Birt C; Yau KK
    J Psychiatry Neurosci; 2000 Sep; 25(4):325-36. PubMed ID: 11022397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combined blockade of cholinergic receptors shifts the brain from stimulus encoding to memory consolidation.
    Rasch BH; Born J; Gais S
    J Cogn Neurosci; 2006 May; 18(5):793-802. PubMed ID: 16768378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological evaluation of the cholinergic system in progressive supranuclear palsy.
    Litvan I; Blesa R; Clark K; Nichelli P; Atack JR; Mouradian MM; Grafman J; Chase TN
    Ann Neurol; 1994 Jul; 36(1):55-61. PubMed ID: 8024262
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of FR121196, a novel cognitive enhancer, on the memory impairment of rats in passive avoidance and radial arm maze tasks.
    Matsuoka N; Maeda N; Yamazaki M; Ohkubo Y; Yamaguchi I
    J Pharmacol Exp Ther; 1992 Nov; 263(2):436-44. PubMed ID: 1432682
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.